United Therapeutics (UTHR) Operating Expenses (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Operating Expenses data on file, last reported at $455.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 10.71% year-over-year to $455.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 9.03% YoY), and the FY2025 full-year result was $1.7 billion, up 12.65% from the prior year.
• Operating Expenses rose to $455.7 million in Q1 2026, from $433.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $455.7 million in Q1 2026 to a low of $173.9 million in Q1 2022.
• A 5-year average of $338.0 million and a median of $354.6 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses plunged 60.82% in 2022 and surged 44.45% in 2024, its largest moves.
• Tracing UTHR's Operating Expenses over 5 years: stood at $315.9 million in 2022, then climbed by 12.25% to $354.6 million in 2023, then increased by 6.66% to $378.2 million in 2024, then advanced by 14.62% to $433.5 million in 2025, then gained by 5.12% to $455.7 million in 2026.
• Business Quant data shows UTHR's Operating Expenses at $455.7 million in Q1 2026, $433.5 million in Q4 2025, and $411.0 million in Q3 2025.